Worldwide Biliary Atresia Market to 2030 – Insights, Epidemiology, and Forecast – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biliary Atresia – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Biliary Atresia market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Biliary Atresia market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Biliary Atresia symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Biliary Atresia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Biliary Atresia market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Biliary Atresia market report gives a thorough understanding of Biliary Atresia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Biliary Atresia treatment algorithms and treatment guidelines for Biliary Atresia in the US, Europe, and Japan.

Biliary Atresia Epidemiology

The Biliary Atresia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

(Read more…)

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology segmented as the Total Incident Cases of Biliary Atresia, Gender-specific Cases of Biliary Atresia, and Type-specific Cases of Biliary Atresia. The report includes the Incident scenario of Biliary Atresia in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Biliary Atresia Epidemiology

The epidemiology segment also provides the Biliary Atresia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Biliary Atresiain 7MM countries was estimated to be 613 cases in 2017.

Biliary Atresia Drug Chapters

The drug chapter segment of the Biliary Atresia report encloses the detailed analysis of Biliary Atresia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Biliary Atresia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no FDA approved therapy for the treatment of Biliary Atresia. The therapeutic market size of Biliary Atresia in the US is mainly accounted for off label treatment options including choleretics such as ursodeoxycholic acid (UDCA), anti-inflammatory medications, steroids, nutritional rehabilitation, and fat-soluble vitamin supplementation.

Biliary Atresia Emerging Drugs

Odevixibat (Albireo) a potent and selective inhibitor of the ileal bile acid transporter (IBAT), also known as apical sodium-dependent bile acid transporter (ASBT), acts locally in the gut, and has minimal systemic exposure at the therapeutic dose. IBAT initiates the transport of bile acids, which flow through the portal vein back to the liver in a process known as enterohepatic circulation. Approximately 95% of bile acids are recirculated via the IBAT to the liver. Accordingly, a product capable of inhibiting the IBAT could lead to a reduction in bile acids returning to the liver and may represent a promising approach for treating cholestatic liver diseases. Therefore, Odevixibat works by decreasing the reabsorption of bile acids from the small intestine to the liver, which reduces the toxic levels of bile acids during the progression of the disease. It exhibits therapeutic intervention by checking the transport of bile acids.

The company presented the data from phase II trial in pediatric cholestasis that supports the potential of odevixibat in Biliary Atresia and Alagille syndrome at the European Association for the Study of the Liver (EASL) annual conference.

Currently, the company is conducting the phase III trial for the treatment of Biliary Atresia. Both FDA and EMA also have granted Orphan Drug Designation to Odevixibat for the treatment of Biliary Atresia.

Products detail in the report

Biliary Atresia Market Outlook

The Biliary Atresia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Biliary Atresia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Biliary Atresia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Biliary Atresia market in 7MM is expected to change in the study period 2017-2030.

The management and diagnosis of BA have not advanced significantly in the past decade, but given recent advances in understanding the timing and potential pathogenesis of BA, it is hopeful that the next decade will bring early diagnostics and novel therapeutics.

Report Highlights

• In the coming years, Biliary Atresia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Atresia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Biliary Atresia. Launch of emerging therapies will significantly impact the Biliary Atresia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Atresia.
• the in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dr97gl

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900